Implementing recommendations for routine mismatch repair (MMR) immunohistochemistry (IHC) testing of endometrial cancer and subsequent patient management.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39842870.
- Also identified by DOI 10.1136/bmjoq-2024-003014 and PMC identifier 11784242.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lynch syndrome is associated with an increased risk of cancer, including endometrial cancer. We audited the introduction of a nurse-led testing and management pathway for Lynch syndrome. All 191 patients diagnosed with endometrial cancer at Somerset NHS Foundation Trust between January 2022 and December 2023 were tested for mis-match repair (MMR) protein immunohistochemistry; germline testing was offered to all 13 who were eligible. Seven patients were diagnosed with Lynch syndrome; all were referred for bowel screening and Helicobacter pylori testing. Information about prophylactic aspirin recommendations was missing for 3/7 patients. We established an effective, nurse-led Lynch syndrome testing pathway, in line with national guidelines.
Medical subject headings
- Endometrial Neoplasms
- Immunohistochemistry
- DNA Mismatch Repair